🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. BOTOX 50 UNITÉS ALLERGAN, poudre pour solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adults aged at least 18 years with painful base-of-thumb osteoarthritis

    phase 3 small molecule active

    1 trial

  2. Bavencio 20 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Solid Tumors

    phase 3 small molecule active

    1 trial

  3. Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis due to exposure of house dust mites

    phase 3 small molecule active

    1 trial

  4. Bendamustine 100 mg Powder for concentrate for Solution for Infusion, Truxima 100 mg concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISONE BIOGARAN 20 mg, scored tablet, Cyclophosphamide Injection 500 mg., Doxorubicin 2 mg/ml Solution for Injection., Truxima 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Revlimid 5 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Revlimid 20 mg hard capsul

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  5. Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline

    connective tissue diseases

    phase 3 small molecule active

    1 trial

  6. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  7. Benralizumab Placebo for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (APFS) for subcutaneous injection. Please refer to the IMPD documentation enclosed., Placebo, Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  8. Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution

    Lacuna Pharma Pty Ltd

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  9. Beyfortus 100 mg solution for injection in pre-filled syringe, Beyfortus 50 mg solution for injection in pre-filled syringe, Abrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent, recombinant)

    Fondazione Telethon ETS

    Respiratory Syncytial Virus (RSV)

    phase 3 small molecule active

    1 trial

  10. Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 320 mg solution for injection in pre-filled pen, Placebo matching test. 0.9% sodium chloride solution for injection (unauthorized)., Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Palmoplantar Pustulosis

    phase 3 small molecule active

    1 trial

  11. Biological Therapies Sodium Ascorbate Solution 30 g in 100 mL Injection, SODIUM CHLORIDE

    Pari Pharma GmbH

    Patient with sepsis complicated by ARDS

    phase 3 small molecule active

    1 trial

  12. Bortezomib STADA 2,5 mg/ml Injektionslösung, Dexamethason 0,5 mg JENAPHARM®, Empliciti 400 mg powder for concentrate for solution for infusion., Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, -, Nodexon 20 mg tabletes, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Nodexon 20 mg tabletės, ELRANATAMAB, Dexamethason 4 mg JENAPHARM®

    Pfizer Australia Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  13. CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  14. CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe

    Camurus Pty Ltd

    gastroenteropancreatic neuroendocrine tumors

    phase 3 small molecule active

    1 trial

  15. CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB

    AstraZeneca AB

    HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

    phase 3 small molecule active

    1 trial

  16. CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution

    Pfizer Australia Pty Ltd

    Colorectal cancer (BRAF V600E-mutant mCRC)

    phase 3 small molecule active

    1 trial

  17. CARBOPLATIN , -, -, PARACETAMOL , CIMETIDINE , DOCETAXEL , PACLITAXEL , MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    pMMR endometrial carcinoma

    phase 3 small molecule active

    1 trial

  18. CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02

    Hoffmann-La Roche

    RET fusion−positive, metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. CARBOPLATIN, PACLITAXEL, DOCETAXEL, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  20. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Psychosis

    phase 3 small molecule active

    1 trial

  21. CBD 100 mg/mL Oral Solution

    COGNITION THERAPEUTICS INC

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  22. CEFTRIAXONE , TEMOCILLIN , Negaban 2 g poudre pour solution injectable/pour perfusion

    Pari Pharma GmbH

    Neisseria gonorrhoeae Infections

    phase 3 small molecule active

    1 trial

  23. CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  24. CHLORURE DE POTASSIUM B. BRAUN 10 % (0,10 g/ml), solution à diluer pour perfusion, GLUCOSE 2,5 % B. BRAUN, solution pour perfusion, MINIRIN 4 microgrammes/ml, solution injectable, SODIUM LACTATE, CHLORURE DE SODIUM 0,9 % AGUETTANT, solution pour perfusion, CHLORURE DE SODIUM HYPERTONIQUE 10 % LAVOISIER, solution à diluer injectable, GLUCOSE 5 % VIAFLO, solution pour perfusion, GADOTERIC ACID

    Pari Pharma GmbH

    Severe hyponatremia and a high risk of rapid SNa overcorrection

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources